FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:2625-2627 December 20, 2007 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Ekberg, H. PubMed Citation

Although protocols differ among transplantation centers, most immunosuppressive strategies for kidney-transplant recipients are built on two core practices: delivery of immunosuppression in two phases, usually termed induction and maintenance, and the concurrent use of several immunosuppressive medications that work at various sites in the cell cycle and have nonoverlapping toxic effects. In general, the induction phase involves the initial use of the same oral immunosuppressive medications that are prescribed at lower doses during long-term maintenance. Induction doses are reduced during the first 2 to 4 months after transplantation until maintenance levels are achieved. Induction may also include the administration of . . . [Full Text of this Article]

Source Information

From the Department of Medicine, Division of Nephrology, University of Michigan Medical School, Ann Arbor.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.